Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shakti Bakshi

Internal Medicine Melbourne, FL Medical Doctor

NPI 1548249535 CMS profile 160362

6550 N Wickham Rd, Suite 2, Melbourne, FL 32940

Open in the dashboard

General payments

$6,851

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shakti Bakshi of Melbourne, FL is reported in the CMS Open Payments database as having received $6,851 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $912 30
2024 General $1,360 38
2023 General $1,722 48
2022 General $927 33
2021 General $896 43
2020 General $694 38
2019 General $340 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shakti Bakshi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shakti Bakshi were reported at $912. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shakti Bakshi Internal Medicine median Middle half National median
2019 $340 $159 $48–$570 $163
2020 $694 $119 $33–$402 $114
2021 $896 $135 $37–$521 $132
2022 $927 $141 $42–$496 $149
2023 $1,722 $149 $45–$519 $160
2024 $1,360 $154 $47–$537 $164
2025 $912 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,604 68 payments
  2. AbbVie, Inc. $511 17 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $472 20 payments
  4. Novo Nordisk Inc $458 16 payments
  5. Pfizer Inc. $439 20 payments
  6. Exact Sciences Corporation $377 14 payments
  7. Janssen Pharmaceuticals, Inc $368 20 payments
  8. Lilly USA, LLC $325 15 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $241 10 payments
  10. Amgen Inc. $231 7 payments
  11. Other $825 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,814 246 payments
  2. Education $37 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,400 45 payments
  2. BREZTRI $749 20 payments
  3. AIRSUPRA $369 3 payments
  4. XARELTO $368 20 payments
  5. Cologuard Collection Kit $299 11 payments
  6. ELIQUIS $282 13 payments
  7. INVOKANA $276 15 payments
  8. UBRELVY $262 8 payments
  9. Kerendia $241 10 payments
  10. RYBELSUS $226 10 payments
  11. Other $3,932 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 156 drugs

Part D claims

8,501

Median for Internal Medicine: 777

Drug cost

$614,941

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 167 $121,194
Jardiance Empagliflozin Brand 99 $85,376
Xarelto Rivaroxaban Brand 88 $78,828
Eliquis Apixaban Brand 77 $70,511
Ozempic Semaglutide Brand 33 $42,522
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 22 $18,592
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $17,916
Tresiba Flextouch U-100 Insulin Degludec Brand 19 $15,286
Tradjenta Linagliptin Brand 17 $9,467
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 14 $9,438

The 10 drugs with the highest cost, of 156 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$179,849

Of which drugs: $189

Medicare patients

236

Average age 76

Services billed

2,406

126 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 50%
Arthritis 39%
Diabetes 35%
Ischemic heart disease 34%
Heart failure 27%
Depression 25%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $369
$369 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $249
$249 167 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $191
$191 22 —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $50
$50 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record